The ‘VITamin D and OmegA-3 Trial’ (VITAL) trial has yielded some positive results indicating that both vitamin D and Omega-3 fatty acids could be promising to effectively prevent cancer death and myocardial infarctions.
The latest results of ‘VITAL’ will be presented during the Annual Meeting of the American Menopause Society in Chicago (U.S)
Nearly 26,000 American men and women participated in the ‘VITAL’ clinical trial. After more than five years of study and treatment, the results show promising signs for certain results. For example, while Omega-3 fatty acids showed only a small but not significant reduction of the main cardiovascular events, which were associated with significant drops in cases of severe heart failure, the greatest benefit of treatment was observed in people with intake. of fish below the median cohort of 1.5 servings per week, but not in those whose intake was above that level. In addition, African Americans seem to experience the greatest risk reductions. The benefits for cardiac health are confirmed by the recent meta-analysis of randomized omega-3 trials.
Similarly, supplementation with vitamin D did not reduce major cardiovascular events or the total incidence of cancer, but was associated with a statistically significant reduction in total cancer mortality among trial participants for at least two years. The effect of vitamin D on reducing cancer mortality is also confirmed by updated meta-analyzes of vitamin D trials to date.
“The pattern of the findings suggests a complex balance of benefits and risks for each intervention and points to the need for additional research to determine which individuals are most likely to obtain a net benefit from these supplements,” said Dr. JoAnn Manson, lead author. of the study of Brigham and Women’s Hospital, affiliate of the Harvard Medical School (U.S).